Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BioForce Nanosciences Announces Confirmation of Its Nanoarray Patent

Abstract:
BioForce Nanosciences, Inc., a wholly-owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH), today announced that it has received notice from the U.S. Patent and Trademark Office (USPTO) that its "Protein Nanoarray" patent (US Pat. No. 6,573,369) has been upheld following a request for re-examination of the previously issued patent by a third party.

BioForce Nanosciences Announces Confirmation of Its Nanoarray Patent

AMES, IA | Posted on October 15th, 2007

BioForce currently commercializes ultramicro arrays that are created using its Nano eNabler(tm) system. These miniaturized diagnostic and discovery tests have features sizes in the one micrometer to twenty micrometer diameter range (a human hair is about 70 micrometers in diameter). The Protein Nanoarray patent covers arrays of proteins having feature sizes of less than one micron squared and containing one or more different protein species. This size scale represents the ultimate level of miniaturization for biological diagnostic and discovery tests.

"This patent has now undergone extraordinary analysis by the USPTO" explained Dr. Eric Henderson, BioForce's founder, CEO and co-inventor of the patent. "Our success in this reexamination gives us confidence that as we make progress toward commercial development of miniaturized diagnostic tests we will have the appropriate intellectual property protection. We have created prototype Protein Nanoarrays as described in this patent and are positioned to begin to commercialize them when the market is ready."

Curtis Mosher, BioForce's Vice President of R&D and co-inventor of the patent, stated, "We continue to make improvements in our Nano eNabler (tm) system that allow it to create extremely miniaturized diagnostics tests. With tests this small a single drop of blood, a tear, or a few cells from a cheek swab can be used for multiple diagnoses with minimal patient impact. This is a fundamental requirement for our long term business goal of patient empowerment and truly personalized medicine."

####

About BioForce Nanosciences, Inc.
BioForce Nanosciences develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization; patterning and cell adhesion; and printing proteins to guide neural cell growth. For more information, visit http://www.bioforcenano.com or call 515-233-8333.

This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the Company's most recent filings with the Securities and Exchange Commission. The Company's actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.

For more information, please click here

Contacts:
RedChip Companies Inc.
Investor Relations
Dave Gentry
1-800-REDCHIP (733-2447) ext 104

http://www.RedChip.com

BioForce Nanosciences Holdings, Inc.
Company Contact:
Greg Brown, CFO
515 233 8333 x118

Copyright © PrimeNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Researchers make flexible glass for tiny medical devices: Glass can bend over and over again on a nanoscale March 27th, 2017

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Announcements

Information storage with a nanoscale twist: Discovery of a novel rotational force inside magnetic vortices makes it easier to design ultrahigh capacity disk drives March 28th, 2017

ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX Technology Platform: Leading-edge I-fuse brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017

Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Patents/IP/Tech Transfer/Licensing

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Intertronics introduce new nanoparticle deagglomeration technology March 15th, 2017

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project